.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
QuintilesIMS
Julphar
Cerilliant
Merck
US Department of Justice
Citi
Moodys
Mallinckrodt
Chubb

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Device for the sustained release of aggregation-stabilized, biologically active agent
Abstract:A device for the sustained release in vivo of a water soluble, biologically active agent wherein the agent is susceptible to aggregation comprising a drug delivery device and aggregation-stabilized, biologically active agent wherein the aggregation-stabilized agent is disposed within the drug delivery device.
Inventor(s): Burke; Paul A. (Oxnard, CA), Zale; Stephen E. (Hopkinton, MA), Tracy; Mark A. (Arlington, MA), Johnson; OluFunmi Lily (Cambridge, MA), Bernstein; Howard (Cambridge, MA), Khan; M. Amin (Dowington, PA), Auer; Henry E. (Chicago, IL)
Assignee: Alkermas Controlled Therapeutics, Inc. (Cambridge, MA)
Filing Date:Sep 22, 1997
Application Number:08/934,830
Claims:1. A sustained release device of a water soluble, biologically active protein or peptide wherein said protein or peptide is susceptible to aggregation, comprising: a) a biocompatible polymeric matrix; and b) particles of aggregation-stabilized, biologically active protein or peptide which include a biologically active protein or peptide and an aggregation stabilizer, wherein the aggregation-stabilizer is a multivalent metal cation from a metal cation component selected from the group consisting of metal salts, metal hydroxides and basic salts of weak acids having a metal cation, the biologically active protein or peptide and the metal cation are complexed and said particles are disposed within the biocompatible polymeric matrix.

2. A sustained release composition of claim 1 wherein the metal cation is a biocompatible multivalent cation selected from the group consisting of Zn.sup.+2, Ca.sup.+2, Cu.sup.+2, Mg.sup.+2 and combinations thereof.

3. A sustained release composition of claim 1 further comprising a second metal cation component, wherein the second metal cation component is dispersed within the biocompatible polymeric matrix.

4. A sustained release composition of claim 3 wherein the second metal cation component is selected from the group consisting of magnesium hydroxide, magnesium carbonate, calcium carbonate, zinc carbonate, magnesium acetate, zinc acetate, magnesium sulfate, zinc sulfate, magnesium chloride, zinc chloride, zinc citrate, magnesium citrate and combinations thereof.

5. A sustained release composition of claim 1 wherein the biocompatible polymeric matrix comprises poly(lactide-co-glycolide).

6. The sustained release device of claim 1 wherein the molar ratio of metal cation component to biologically active protein or peptide is from about 1:2 to about 100:1.

7. The sustained release device of claim 6 wherein the molar ratio of metal cation component to biologically active protein or peptide is from about 2:1 to about 10:1.

8. A sustained release device of a water soluble, biologically active protein or peptide wherein said protein or peptide is susceptible to aggregation, comprising: a) a biodegradable polymeric matrix; and b) particles of aggregation-stabilized, biologically active protein or peptide which include a biologically active protein or peptide and an aggregation stabilizer wherein the aggregation-stabilizer is a multivalent metal cation from a metal cation component selected from the group consisting of metal salts, metal hydroxides and basic salts of weak acids having a metal cation, the biologically active protein or peptide and the metal cation are complexed and said particles are disposed within the biodegradable polymeric matrix.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Colorcon
US Department of Justice
Dow
Healthtrust
Farmers Insurance
McKesson
Express Scripts
Fish and Richardson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot